11. The crystalline compound of claim 10, having 2θ values 8.29; 16.10; 17.39; 19.24; 19.54; 19.74; 20.33; 20.78; 20.98; 21.18; 21.58; 22.03; 22.78; 22.98; 25.53; 28.48; and 29.48.

12. The crystalline compound of claim 11, having 2θ values 8.29; 13.12; 15.79; 16.10; 16.69; 17.39; 19.03; 19.24; 19.54; 19.74; 20.33; 20.78; 20.98; 21.18; 21.58; 22.03; 22.78; 22.98; 23.95; 24.14; 24.48; 24.64; 25.14; 25.53; 25.87; 26.89; 27.18; 27.67; 28.02; 28.13; 28.48; 28.98; 29.34; 29.48; and 29.92.

13. The crystalline compound of claim 12, having an XRD pattern substantially as shown in FIG. 1, labeled Form 2.

14. A pharmaceutical composition comprising the crystalline compound of any one of claims 1-13 and one or more pharmaceutically acceptable excipients.

15. A method for preparing a crystalline compound having the structure of formula (I):



(I);

comprising:

a) providing a mixture of a compound of formula (I) in a solvent; and

b) crystallizing the compound of formula (I) from the mixture comprising the compound of formula (I).

16. The method of claim 15, wherein the crystalline compound is anhydrous.

17. The method of claim 15, wherein the crystalline compound is a solvate.

18. The method of claim 17, wherein the solvate is a dimethylsulfoxide solvate.

19. The method of claim 15, wherein the solvent is methanol or water.

20. The method of claim 18, wherein the solvent is dimethylsulfoxide.

21. The method of any one of claims 15-20, wherein the mixture comprising the compound of formula (I) is a solution, and the step of crystallizing the compound of formula